An Alkylation-tolerant, Mutator Human Cell Line is Deficient in Strand-specific Mismatch Repair
Overview
Authors
Affiliations
The human lymphoblastoid MT1 B-cell line was previously isolated as one of a series of mutant cells able to survive the cytotoxic effects of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). MT1 cells nevertheless remain sensitive to mutagenesis by MNNG and display a mutator phenotype. These phenotypes have been attributed to a single genetic alteration postulated to confer a defect in strand-specific mismatch repair, a proposal that attributes the cytotoxic effect of DNA alkylation in wild-type cells to futile attempts to correct mispairs that arise during replication of alkylated template strands. Our results support this view. MNNG-induced mutations in the HPRT gene of MT1 cells are almost exclusively G.C-->A.T transitions, while spontaneous mutations observed in this mutator cell line are single-nucleotide insertions, transversions, and A.T-->G.C transitions. In vitro assay has demonstrated that the MT1 line is in fact deficient in strand-specific correction of all eight base-base mispairs. This defect, which is manifest at or prior to the excision stage of the reaction, is due to simple deficiency of a required activity because MT1 nuclear extracts can be complemented by a partially purified HeLa fraction to restore in vitro repair. These findings substantiate the idea that strand-specific mismatch repair contributes to alkylation-induced cytotoxicity and imply that this process serves as a barrier to spontaneous transition, transversion, and insertion/deletion mutations in mammalian cells.
Fujii S, Fuchs R Int J Mol Sci. 2024; 25(15).
PMID: 39125763 PMC: 11311527. DOI: 10.3390/ijms25158192.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby G Nat Commun. 2024; 15(1):1957.
PMID: 38438348 PMC: 10912752. DOI: 10.1038/s41467-024-45979-5.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby G bioRxiv. 2023; .
PMID: 37905107 PMC: 10614844. DOI: 10.1101/2023.10.16.562506.
DNA mismatch repair in cancer immunotherapy.
Guan J, Li G NAR Cancer. 2023; 5(3):zcad031.
PMID: 37325548 PMC: 10262306. DOI: 10.1093/narcan/zcad031.
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.
Nazerai L, Willis S, Yankilevich P, Di Leo L, Maria Bosisio F, Frias A Oncoimmunology. 2022; 12(1):2158610.
PMID: 36545256 PMC: 9762757. DOI: 10.1080/2162402X.2022.2158610.